Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
about
Advancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaDetection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Next generation MRD.Characterizing immune repertoires by high throughput sequencing: strategies and applications.Dynamics of the cytotoxic T cell response to a model of acute viral infectionIgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?A Public Database of Memory and Naive B-Cell Receptor SequencesComparative Analysis of Immune Repertoires between Bactrian Camel's Conventional and Heavy-Chain AntibodiesContribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.Short-term assessment of BCR repertoires of SLE patients after high dose glucocorticoid therapy with high-throughput sequencingMinimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing.Immunotherapy biomarkers 2016: overcoming the barriers.Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.T-cell receptor profiling in cancer.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?High-throughput sequencing of the T-cell receptor repertoire: pitfalls and opportunities.Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.Immune monitoring technology primer: immunosequencing.Immunoglobulin rearrangement analysis from multiple lesions in the same patient using next-generation sequencing.TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination.The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL.Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing.High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges.Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues.Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments.Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.Direct measurement of B-cell receptor repertoire's composition and variation in systemic lupus erythematosus.Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.High-throughput sequencing reveals novel features of immunoglobulin gene rearrangements in Burkitt lymphomaHigh-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesisSimple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
P2860
Q28087291-28EDE2D1-8A3B-4F1E-AFD5-D734E845620FQ33614375-20193BBA-60F5-4F94-AC9A-8F9ABD37C25BQ34364350-2B4DB74B-9613-48BD-832E-4F17088535B3Q34406955-99AA2512-B11E-4B8A-B0E9-B2AD8BED39C1Q35327599-B2E1F4F1-1844-4B47-8733-726C69EF32F7Q35640949-785FF530-3124-48A5-9286-C4FBE0F38A25Q35662007-03E3B83E-AF4E-4308-B065-83B3F98D2F93Q35992927-569A95C4-B722-499B-A08C-A1DFEC1BB79EQ36101141-21135369-D53D-4F93-A74A-D1D6D92F955AQ36121467-AB15595C-D1EE-4660-B58A-16608D99FBCDQ36383913-CD3EC86A-0AE5-48E0-821D-816E9085416AQ36501620-A4727494-ED39-4D16-94E6-8C164F572319Q37307811-60182A02-6A9B-4BAD-8851-F3A0BF8ABB77Q37713438-2B02A73E-9798-46C7-9AD6-908150D6CBDDQ38438814-6A72BE00-260E-4C8E-BF66-CEF0931DA1E6Q38592595-8627A4FB-2B9C-4320-B53A-5071C54359EAQ38672646-6D834527-2455-4115-BA25-52165166A127Q38815331-84D66CB0-5372-4134-8949-7F9CDA2345E7Q39026323-4AFA2616-D43F-406C-9ADC-47917930D945Q39035188-ED149F1F-EB21-4B76-BF50-649B58EECE13Q39420711-544ACBE6-95F2-41B9-94E4-DCF4EE2648DCQ41138470-281FCAF7-A0DA-4132-A401-88471715E0F8Q42147130-321D4FEF-117E-4B7C-98B1-A6BBF16892F0Q42169344-A18E7D31-1D64-4A9F-A5F3-F919C3D36AA7Q42912272-BB58F704-DDCE-43C3-87FD-7DD2AAB89BC9Q46103668-E79A1CD3-3D5D-4D40-A833-788B8039B86DQ48268599-C19D87A3-2BBE-41AC-B55C-E4B303437682Q48298664-71BE3684-71EB-4089-BAB9-6751B256FD17Q48762439-0093352E-8D63-406A-9CA4-CF3892689968Q50020985-8B517883-D8F7-451E-B1A0-C45CBFC3E6DCQ50223693-2954E1D8-3FD0-48D2-AA6D-F9E1E67B3C2CQ51217328-B53E1B1C-00FE-437F-BD26-C7423930B720Q52735368-5EAE4DDF-E537-4740-98CF-3FDED79340B8Q56913436-833C4095-6FA8-4B4B-B7B8-B8D1AD643299Q56913678-82FC131A-EF01-4BB4-955A-59D4893C8607Q58724470-BDC80B52-4AB7-4A36-BFA6-0C84C3254852
P2860
Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 June 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Detection of minimal residual ...... -throughput sequencing of IGH.
@en
Detection of minimal residual ...... -throughput sequencing of IGH.
@nl
type
label
Detection of minimal residual ...... -throughput sequencing of IGH.
@en
Detection of minimal residual ...... -throughput sequencing of IGH.
@nl
prefLabel
Detection of minimal residual ...... -throughput sequencing of IGH.
@en
Detection of minimal residual ...... -throughput sequencing of IGH.
@nl
P2093
P2860
P1476
Detection of minimal residual ...... -throughput sequencing of IGH.
@en
P2093
Anna Sherwood
Anne Angiolillo
Brent L Wood
Bryan Howie
Christopher Carlson
David Williamson
Harlan Robins
Ilan Kirsch
Jennifer Vogt
P2860
P304
P356
10.1158/1078-0432.CCR-13-3231
P407
P577
2014-06-26T00:00:00Z